Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2021

Feb 17, 2021

30291_dirs_2021-02-17_c1483802-dbe5-4c65-a771-784e473836bd.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2021-02-12

Reporting Person: Vounatsos Michel (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-12 Common Stock F 7248 $278.03 Disposed 43905.286 Direct
2021-02-12 Common Stock M 5693 Acquired 49598.286 Direct
2021-02-12 Common Stock M 5259 Acquired 54857.286 Direct
2021-02-12 Common Stock M 5337 Acquired 60194.286 Direct
2021-02-12 Common Stock F 2525 $278.03 Disposed 57669.286 Direct
2021-02-12 Common Stock F 2333 $278.03 Disposed 55336.286 Direct
2021-02-12 Common Stock F 2367 $278.03 Disposed 52969.286 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-02-12 Restricted Stock Unit $0 M 5693 Disposed 2021-02-12 Common Stock (5693) Direct
2021-02-12 Restricted Stock Unit $0 J 6419 Disposed 2021-02-12 Common Stock (6419) Direct
2021-02-12 Restricted Stock Unit $0 M 5259 Disposed 2022-02-12 Common Stock (5259) Direct
2021-02-12 Restricted Stock Unit $0 J 7263 Disposed 2022-02-12 Common Stock (7263) Direct
2021-02-12 Restricted Stock Unit $0 M 5337 Disposed 2023-02-12 Common Stock (5337) Direct
2021-02-12 Restricted Stock Unit $0 J 7221 Disposed 2023-02-12 Common Stock (7221) Direct

Footnotes

F1: Represents shares withheld to satisfy the withholding tax liability due upon the vesting of shares, as previously disclosed by reporting person on January 29, 2021.

F2: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

F3: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.